168 related articles for article (PubMed ID: 38516924)
1. Exploring Product Release from Yeast Cytosine Deaminase with Metadynamics.
Croney KA; McCarty J
J Phys Chem B; 2024 Apr; 128(13):3102-3112. PubMed ID: 38516924
[TBL] [Abstract][Full Text] [Related]
2. Product release is rate-limiting in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Yao L; Li Y; Wu Y; Liu A; Yan H
Biochemistry; 2005 Apr; 44(15):5940-7. PubMed ID: 15823054
[TBL] [Abstract][Full Text] [Related]
3. Role of glutamate 64 in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Wang J; Sklenak S; Liu A; Felczak K; Wu Y; Li Y; Yan H
Biochemistry; 2012 Jan; 51(1):475-86. PubMed ID: 22208667
[TBL] [Abstract][Full Text] [Related]
4. Transduction of yeast cytosine deaminase mediated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine.
Lee H; Ryu J; Kim KA; Lee KS; Lee JY; Park JB; Park J; Choi SY
Exp Mol Med; 2004 Feb; 36(1):43-51. PubMed ID: 15031670
[TBL] [Abstract][Full Text] [Related]
5. Product release mechanism and the complete enzyme catalysis cycle in yeast cytosine deaminase (yCD): A computational study.
Zhao Y; She N; Zhang X; Wang C; Mo Y
Biochim Biophys Acta Proteins Proteom; 2017 Aug; 1865(8):1020-1029. PubMed ID: 28478051
[TBL] [Abstract][Full Text] [Related]
6. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Yi BR; Kim SU; Kim YB; Lee HJ; Cho MH; Choi KC
Oncol Rep; 2012 Jun; 27(6):1823-8. PubMed ID: 22426744
[TBL] [Abstract][Full Text] [Related]
8. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Kievit E; Nyati MK; Ng E; Stegman LD; Parsels J; Ross BD; Rehemtulla A; Lawrence TS
Cancer Res; 2000 Dec; 60(23):6649-55. PubMed ID: 11118048
[TBL] [Abstract][Full Text] [Related]
9. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Altanerova U; Jakubechova J; Benejova K; Priscakova P; Repiska V; Babelova A; Smolkova B; Altaner C
Int J Cancer; 2021 Jan; 148(1):128-139. PubMed ID: 32621791
[TBL] [Abstract][Full Text] [Related]
10. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
[TBL] [Abstract][Full Text] [Related]
11. Strong enhancement of recombinant cytosine deaminase activity in Bifidobacterium longum for tumor-targeting enzyme/prodrug therapy.
Hamaji Y; Fujimori M; Sasaki T; Matsuhashi H; Matsui-Seki K; Shimatani-Shibata Y; Kano Y; Amano J; Taniguchi S
Biosci Biotechnol Biochem; 2007 Apr; 71(4):874-83. PubMed ID: 17420581
[TBL] [Abstract][Full Text] [Related]
12. Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.
Stolworthy TS; Korkegian AM; Willmon CL; Ardiani A; Cundiff J; Stoddard BL; Black ME
J Mol Biol; 2008 Mar; 377(3):854-69. PubMed ID: 18291415
[TBL] [Abstract][Full Text] [Related]
13. Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
Zamboni S; Mallano A; Flego M; Ascione A; Dupuis ML; Gellini M; Barca S; Cianfriglia M
Int J Oncol; 2008 Jun; 32(6):1245-51. PubMed ID: 18497986
[TBL] [Abstract][Full Text] [Related]
14. PEGylation of yeast cytosine deaminase for pretargeting.
Xiong MP; Kwon GS
J Pharm Sci; 2005 Jun; 94(6):1249-58. PubMed ID: 15858841
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of a novel chitosan based E. coli cytosine deaminase nanocomposite for potential application in prodrug enzyme therapy.
Yata VK; Ghosh SS
Biotechnol Lett; 2011 Jan; 33(1):153-7. PubMed ID: 20960222
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.
Yamada S; Kuroda T; Fuchs BC; He X; Supko JG; Schmitt A; McGinn CM; Lanuti M; Tanabe KK
Cancer Gene Ther; 2012 Mar; 19(3):160-70. PubMed ID: 22076044
[TBL] [Abstract][Full Text] [Related]
17. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
18. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy.
Li C; Penet MF; Wildes F; Takagi T; Chen Z; Winnard PT; Artemov D; Bhujwalla ZM
ACS Nano; 2010 Nov; 4(11):6707-16. PubMed ID: 20958072
[TBL] [Abstract][Full Text] [Related]
19. Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles.
Roy S; Curry SD; Corbella Bagot C; Mueller EN; Mansouri AM; Park W; Cha JN; Goodwin AP
ACS Nano; 2022 Oct; 16(10):15873-15883. PubMed ID: 36129781
[TBL] [Abstract][Full Text] [Related]
20. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase.
Hamstra DA; Rice DJ; Fahmy S; Ross BD; Rehemtulla A
Hum Gene Ther; 1999 Aug; 10(12):1993-2003. PubMed ID: 10466633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
